Seqirus to expand flu vaccine production site in Liverpool with £22 million investment
Seqirus, the world’s second largest influenza vaccine provider, has announced a £22.1 million ($31.2 million) investment for its UK manufacturing site in Liverpool.
The company, which is part of Australian biotech firm CSL Limited (ASX: CSL), is going to develop a new £15.3 million manufacturing facility to support the production of influenza vaccines at its Speke site. The announcement came as Seqirus today celebrated the opening of a £6.8 million investment in new warehousing facilities at the site.
Seqirus was created in November 2015 following CSL’s acquisition of the Novartis influenza vaccines business and the subsequent merger with its existing vaccines and pharmaceutical business, bioCSL. The combined company has over 2,000 employees and operations in more than 20 countries, and reported sales for the first-half of fiscal year 2016 of $519 million (The Pharma Letter February 16).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze